Abstract
Introduction
For solid tumors larger than 2 mm3, growth and metastasis depend on neovascularization, 1 with such tumors relying on neovascularization to provide metabolically necessary substances to support growth. 2 tumor neovascularization is a complex process regulated by multiple factors, and blocking angiogenesis by inhibiting the expression of promotive factors has become an important strategy for antitumor therapy.3,4
Endostatin is an endogenous anti-angiogenic factor that was first isolated from mouse vascular endothelial cell tumor cultures by O'Reilly in 1996. 5 It is a carboxy-terminal-hydrolysed fragment derived from collagen XVIII that has a molecular weight of 20 kDa and contains 184 amino acids. Endostatin inhibits tumor angiogenesis and growth by blocking the migration, proliferation, and lumen formation of vascular endothelial cells. 6
A previous report showed that recombinant human endostatin (rh-endostatin) prepared using
A new rh-endostatin drug for administration by injection was used in the current study; this formulation was developed by Suzhou Zhongkai Biopharmaceutical Factory and the Institute of Biomedical Research, Jiangsu Wuzhong Pharmaceutical Group Co. This rh-endostatin drug was prepared using an
Materials and Methods
Patient Selection
The Tianjin Medical University Cancer Institute and Hospital ethics committee approved this study on August 24, 2016, and the approval number is E2016138.
Each included patient signed an written informed consent form prior to enrolment, which included a description of the study drug and study procedures, as well as the patient's privacy, risks, benefits and compensation. The enrolled patients met the following inclusion criteria: aged 18 to 70 years, BMI of 19 to 28 kg/m2, ECOG status of 0 to 2, expected survival time ≥3 months, pathologically confirmed advanced solid tumors refractory to standard therapy or for which there was no standard therapy, and adequate organ function. Adequate organ function was defined as a thrombin time and prothrombin time of 1.5 × the upper limit of normal, without a bleeding tendency or thrombosis; an absolute neutrophil count ≥1.5 × 109/L; a platelet count of ≥100.0 × 109/L; a haemoglobin concentration ≥90.0 g/L; and bilirubin, AST, ALT, and serum creatinine 1.5 × the upper limit of normal.
The exclusion criteria were any previous chemotherapy, biotherapy, immunotherapy or radiotherapy within 4 weeks of enrolment or having undergone any previous major surgery within the previous 3 weeks. Additionally, patients were excluded if they had a history of severe cardiovascular disease, such as uncontrollable hypertension, myocardial infarction, typical angina pectoris, congestive heart failure, severe arrhythmia, prolonged QT interval syndrome, atrioventricular block, cerebral infarction or brain hemorrhage. Patients with severe infection, uncontrolled malignant pleural or abdominal effusion, mental illness, primary or metastatic brain tumor, a history of HIV or chronic hepatitis B or C infection, syphilis, an allergic constitution, or pregnancy and patients who were breastfeeding were also excluded.
In error, we did not prospectively register this trial, but we have now registered it retrospectively at the Research Registry https://www.researchregistry.com/: registration number 7187.
Study Design and Rh-Endostatin Administration
This phase I trial was designed as a single-centre, single-arm, nonrandomized, open-label, dose-escalation study. The trial was divided into 2 parts: a single-dose part and a multiple-dose part. Rh-endostatin was administered as a 120-min intravenous injection only once in the single-dose part and as a daily 120-min intravenous injection for 14 days in the multiple-dose part. Based on the results of preclinical pharmacodynamic, toxicological and pharmacokinetic studies on rh-endostatin, as well as the phase I clinical doses of similar products used domestically and abroad, 3 dose comparison groups, namely, 5 mg/m2, 7.5 mg/m2 and 10 mg/m2, were designed for both parts, and 6 to 8 patients with advanced solid tumors were allocated to each dose comparison group. Any adverse events that occurred during the clinical trial were recorded according to CTCAE 4.03. If there was no DLT in 1/3 or more of the subjects enrolled in a dose group, the next highest dose comparison group was tested; if DLT was observed, dose escalation was ended.
Sample Preparation and Pharmacokinetic Assessment
For the single-dose part of the study, blood was collected before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, and 72 h after dosing (measured from the start of the intravenous injection). For the multiple-dose part, blood was collected at the following time points: before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 h after dosing on day 1, before dosing on days 12, 13, and 14, and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 48 and 72 h after dosing on day 14. Three milliliters of whole blood was collected at each time point.
After the blood had clotted, each sample was centrifuged at 2000 rpm and 4 °C for 10 min, and at least 0.6 mL of the resulting serum was transferred to a cryogenic tube for testing, with the remaining serum being transferred to a back-up tube. The samples were stored upright at −40 °C until use and were sent to the laboratory for determination of rh-endostatin concentrations by electrochemiluminescence assay.
The following relevant single-dose pharmacokinetic parameters were measured: t1/2β, MRT, AUC0−t, AUC0−τ, AUC0−∞, Vz, CL, Cmax, and Tmax, among others. The pharmacokinetic parameters for the multiple-dose part of the study were t1/2β ss, AUC0−τ, AUC0−t ss, AUC0−∞ ss, Vz ss, CLss, Cmax ss, Cmin ss, and Tmax ss, among others.
Immunogenicity Assessment
To assess the immunogenicity of rh-endostatin, detection of antibodies against rh-endostatin was performed. Blood samples (3 mL) were collected before the first dose and on day 7 ± 1 of the single-dose part or on day 21 ± 1 of the multiple-dose part. After the blood had clotted, the samples were centrifuged at 2000 rpm and 4 °C for 10 min. At least 0.8 mL of the resulting serum was transferred to a cryogenic tube for testing, and the remaining serum was transferred to a back-up tube. Anti-rh-endostatin antibodies in serum were detected using the Bridging-ECL method.
Statistical Methods
WinNonlin 6.3 was used for the pharmacokinetic analyses. No comparative statistics were used. Data are presented in a descriptive manner. Descriptive statistics were used in this study. Mean and standard deviations were used for Continuous data. The frequency and percentage are provided for count data.
Results
Patient Characteristics and Treatments
From December 2016 to December 2017, 24 patients with advanced solid tumors were enrolled in the single-dose part, and 25 patients were enrolled in the multiple-dose part (Table 1).
Patient Characteristics.
All subjects in the single-dose part completed the entire study according to the protocol. One subject in the 5-mg/m2 dose group and 2 in the 10-mg/m2 dose group were excluded from the pharmacokinetic analysis because blood was drawn from the infusion side of the limb, which might have affected the drug concentration in these samples. In the multiple-dose part, 3 patients withdrew from the study. Among these 3 subjects, 1 in the 5-mg/m2 dose group experienced grade 1 haemoptysis during the trial and, given the mechanism of action of the study drug, withdrew from the trial due to the risk of adverse event exacerbation. This participant had advanced central lung cancer, and the adverse event in question was considered to be due to the disease itself and might not have been related to rh-endostatin. The second subject, who was also in the 5-mg/m2 dose group, withdrew from the trial due to grade 1 palpitations that were unlikely to be related to rh-endostatin treatment according to the researcher's judgement. The third subject, who was in the 10-mg/m2 dose group, withdrew for personal reasons. After all exclusions, 22 subjects remained in the multiple-dose part and were included in the pharmacokinetic analysis.
Toxicities
Overall, rh-endostatin treatment was well tolerated, with only grade 1 to 2 drug-related adverse events in the single-dose part (Table 2). There were no DLTs or drug-related serious adverse events (SAEs). The grade 2 drug-related adverse events observed were a prolonged QT interval on ECG (1 patient in the 5-mg/m2 group, 1 patient in the 7.5-mg/m2 group, and 3 patients in the 10-mg/m2 group), anemia (1 patient in the 10-mg/m2 group), and neutropenia (1 patient in the 10-mg/m2 group).
Drug-related Adverse Events in the Single-dose and Multiple-dose Parts.
Additionally, no DLTs or drug-related SAEs occurred in the multiple-dose group (Table 2). All drug-related adverse events were grade 1 to 2, except for 2 grade 3 adverse events in the 5 mg/m2 dose group (1 patient with increased ALT and AST), which were considered to possibly be related to the study drug. Twenty-three grade 2 drug-related adverse events occurred during the study, the most common of which was a prolonged QT interval on ECG.
Pharmacokinetics
The pharmacokinetic parameters of the subjects in the single-dose part are shown in Table 3, and time curves for the mean rh-endostatin blood concentration are shown in Figure 1. In all dose groups, rh-endostatin blood concentrations increased gradually with time after dosing; the Cmax was reached at approximately 2.00 h after dosing in most subjects, followed by a slow decrease in the blood concentration, which generally fell back to below the assayed lower limit of quantification (LLOQ) within 12 h after dosing (78.13 ng/mL). The Cmax and AUC0−t displayed a linear pharmacokinetic profile with increasing dose administration, as illustrated in Figure 1.
The 8-h linear curve showing the mean blood concentration of rh-endostatin over time in the single-dose part of the study (A); the Cmax (B) and AUC0-t (C) in each single-dose group.
Pharmacokinetic Parameters in the Single-dose Part (mean ± SD) and Multiple-dose Part (mean ± SD).
Note: a Concentration data were not available for this time point because more than 1/3 of the individual data points were below the LLOQ. The parameters AUC0−∞, R2−a, λz, t1/2, AUC%Extrap, Vz ss, and CLss were not included in the descriptive statistics because the linear regression fit R2−a of <0.800 or AUC%Extrap of > 20% of the elimination phase did not meet the statistical requirements.
The pharmacokinetic parameters of the subjects in the multiple-dose part are shown in Table 3, and the mean blood concentration-time curves are shown in Figure 2. The steady-state Tmax was approximately 2 h after dosing, and the blood concentration fell back to below the LLOQ (78.13 ng/mL) approximately 12 h after completion of the first dose infusion. The trough concentrations of the drug were around the LLOQ on day 12, day 13 or day 14 after dosing.
Mean blood concentration-time curves in the 5-mg/m2 group (A), 7.5-mg/m2 group (B), and 10-mg/m2 group (C) in the multiple-dose part of the study.
Compared with the first-dose Cmax and AUC0–24 values, the Cmax ss and AUC0−τ values were elevated in the 5-mg/m2 group after multiple infusions (Figure 3). For 5, 7.5, and 10 mg/m2, the mean cumulative ratio (RCmax) values were 1.61 ± 0.631, 1.12 ± 0.175, and 1.11 ± 0.132, respectively, and the RAUC values were 2.28 ± 0.743, 1.04 ± 0.357, and 1.20 ± 0.358, respectively, indicating that a 14-day infusion with a concentration of 7.5 mg/m2 or 10 mg/m2 did not result in significant accumulation in the subjects but that repeated administration at 5 mg/m2 may result in some accumulation. The confidence interval method was used to evaluate the pharmacokinetic profile after multiple dosing, and neither the trend in Cmax ss nor that in AUC0−τ was characterized by linear pharmacokinetics in the dose range of 5 to 10 mg/m2 .
Cmax (A) and AUC (B) on day 1 and day 14 in each multiple-dose group.
Anti-drug Antibody (ADA) Assays
All the subjects tested negative for ADAs before dosing and during the follow-up period in each single-dose comparison group. Among the multiple-dose comparison groups, only 1 sample from the 10-mg/m2 group was positive for ADAs.
Discussion
Endothelial inhibitors are pan-targeted endogenous broad-spectrum anti-angiogenic factors with multiple mechanisms of action. These mechanisms include actions on vascular endothelial growth factor (VEGF) receptors to prevent VEGF binding to endothelial cells; downregulation of angiogenic factors, blocking degradation of the basal lamina by matrix metalloproteinase-2 (MMP-2), inhibiting endothelial cell proliferation and migration, and promoting endothelial cell apoptosis. 13 The recombinant human vascular endothelial inhibitor Endostar has the advantages of a broad antitumor spectrum, mild toxicity, and less resistance to continuous medication; it is widely used to treat non-small-cell lung cancer, colorectal cancer, breast cancer, malignant melanoma and other solid tumors and can be used to control malignant effusion.14–20
Three dose groups, namely, 5, 7.5, and 10 mg/m2, were designed for this study. In the current trial, patients in each dose group were able to tolerate the single dose as well as multiple doses, and no DLTs or drug-related SAEs were observed.
The incidences of cardiotoxicity with rh-endostatin treatment reported in the literature range from 6.4% to 13.2%, and these toxicities include mainly myocardial ischemia, electrocardiographic abnormalities and proiosystole. 21 In the phase I clinical trial of Endostar reported by YANG Lin et al., the main adverse events were arrhythmia, paroxysmal supraventricular tachycardia, ventricular proiosystole, and abnormal ECG T waves. 22 Additionally, the adverse cardiovascular events in 61 patients with non-small-cell lung cancer treated with Endostar reported by Wenjing MENG et al. included ECG abnormalities, D-dimer anomalies, platelet abnormalities, and blood pressure fluctuations. 23 Among these adverse events, ECG abnormalities had the highest incidence, and older patients were more likely to have ECG abnormalities and blood pressure fluctuations than younger patients. Nevertheless, all of these adverse events improved after treatment ended.
The mechanism of rh-endostatin cardiotoxicity is likely to be related to cardiomyocyte apoptosis and angiogenesis inhibition. The former is an important mode of cardiomyocyte death, and studies have shown that cardiomyocyte apoptosis plays an important role in the pathophysiology of various cardiovascular diseases and the development of cardiotoxicity for many drugs.24–26 Cardiomyocyte apoptosis has multiple triggers, such as excessive cardiac anterior and posterior loads, calcium overload in cardiomyocytes, myocardial ischemia, and hypoxia. Qin Jing et al. 27 found significant pathological changes in the rat myocardium after high-dose (12 mg/kg) Endostar administration from 4 weeks to 8 weeks, involving enlarged myocardial cell gaps, disruptions in the myocardial cell arrangement, localized myocardial cell nuclear lysis, subepicardial inflammatory cell infiltration, and blurred myocardial cell structure. Structural damage to the mitochondria and significant expansion of the sarcoplasmic reticulum in cardiomyocytes were also observed by electron microscopy, suggesting that mitochondrial pathway-induced myocardial apoptosis may be an important mechanism of Endostar-induced cardiotoxicity. Cardiomyocytes are terminally differentiated cells. Thus, as apoptosis increases, the number of active cardiomyocytes decreases, which in turn leads to impairment of cardiac function and induces various cardiovascular events, such as heart failure, arrhythmia, and myocardial ischemia. In addition, as an angiogenesis inhibitor, rh-endostatin acts on the VEGF receptor cell signaling pathway, blocking autophosphorylation of VEGF receptors and activation of certain protein kinases to inhibit neovascularization, which may cause cardiac ischemia and hypoxia and induce a variety of cardiotoxicities.
In this trial, the observed adverse events included mainly various arrhythmias and ECG, blood pressure, coagulation, and hematological or liver function abnormalities, the majority of which were grade 1 to 2; indeed, the only drug-related grade 3 adverse event was elevated ALT and AST. A detailed assessment of a patient's history of cardiovascular disease prior to treatment, selection of an appropriate treatment population, close monitoring of cardiac function during treatment, and avoidance of treatment in combination with cardiotoxic drugs will help to prevent cardiovascular events.
Kisker et al. showed that rh-endostatin has a tumor-shrinking effect at steady-state blood concentrations of 200 to 300 ng/mL after application. 28 After daily administration at 15 mg/m2, the Cmin ss of the rh-endostatin produced by EntreMed, USA, was 48 ± 25 ng/mL, the Cmax ss was 394 ± 55 ng/mL, and the AUC0–24 was 31 ± 15 µg•min/mL. 8 Bi Hu et al. showed that the blood concentration of rh-endostatin increased gradually over time after a daily intravenous drip at 10 mg/m2, and the peak blood concentration was generally within 2 h. The blood concentration decreased immediately after the end of dosing and basically returned to the pre-dosing level within 12 h after the completion of dosing. After 28 days of dosing, the Cmin ss was 166.31 ± 53.36 ng/mL, the Cmax ss was 861.29 ± 160.25 ng/mL, and the AUC0–24 was 40.32 ± 8.56 µg•h/mL. 29 The phase I clinical trial by YANG Lin et al. showed that after 28 days of intravenous dosing with Endostar at 7.5 mg/m2 daily, the Cmin ss was 220 ± 120 ng/mL, the Cmax ss was 870 ± 470 ng/mL, and the AUC0–24 was 2660 ± 1760 ng•h/mL. In this study, after 14 days of 7.5 mg/m2 daily infusion, the Cmin ss was 37.8 ± 52.9 ng/mL, the Cmax ss was 531 ± 106 ng/mL, and the AUC0–24 3620 ± 1670 ng•h/mL; however, after 14 days of daily infusion with 10 mg/m2 rh-endostatin, the Cmin ss was 86.9 ± 49.8 ng/mL, the Cmax ss was 864 ± 166 ng/mL, and the AUC0–24 was 4670 ± 1900 ng•h/mL. 22 The pharmacokinetic characteristics of the drug after continuous administration were similar to those of Endostar and other rh-endostatin intravenous injections, and the Cmin ss and Cmax ss in the same dose group were slightly lower than those of Endostar, but they were above the blood concentration for effective tumor suppression. As rh-endostatin is a protein-based biological agent, its biological activity requires correct folding into a specific 3-dimensional structure. 30 This may explain the differences in the pharmacokinetic parameters of drugs of the same class, such those described above, and these discrepancies may be related to differences in the production process, molecular structure, stability, purity, and effective folding.
There is a very important relationship between changes in the conformation of drug molecules and their biological activity, which is due to the fact that the interaction between a drug and a receptor requires complementarity in the conformation of both. If the conformation of a drug molecule changes, the physicochemical properties and charge density of the drug molecule will change, which in turn will affect the binding of the drug to the receptor, the absorption and transport of the drug in the body, and ultimately affect the therapeutic effect of the drug, and even have unexpected adverse events. The rh-endostatin formulation prepared by Jiangsu Wuzhong Pharmaceutical Group Co., Ltd with E. coli as the expression system and used in this study has a higher purity than the similar product prepared by EntreMed, Inc. using Pichia as the expression system. And it has the same amino acid sequence as the natural human endothelial inhibitor, without any modification or reconstruction. Therefore, the dose administered in the current study was only approximately one-tenth that of EndreMed.
The following were calculated in this study: mean cumulative ratio RCmax of 1.61 ± 0.631 and RAUC of 2.28 ± 0.743 after multiple doses of 5 mg/m2; RCmax of 1.12 ± 0.175 and RAUC of 1.04 ± 0.357 after multiple doses of 7.5 mg/m2; RCmax of 1.11 ± 0.132 and RAUC of 1.20 ± 0.358 after multiple doses of 10 mg/m2. Based on RCmax results for each dose group, it was inferred that no significant accumulation occurred in the subjects after 2 h of daily administration of rh-endostatin at 7.5 mg/m2 or 10 mg/m2 for 14 days, though some accumulation appeared to have occurred in the 5 mg/m2 group.
In this study, only 3 dose groups were preset. Although no DLTs or drug-related SAEs occurred, this study drug did not continue to climb to higher doses, which was due to previously obtained preclinical pharmacodynamic, toxicological and clinical pharmacokinetic results. According to the results of similar drug studies, it was essentially determined that this study drug had reached a therapeutically effective dose. In addition, no other adverse events such as fever, rash, and diarrhea, which occurred with similar products, were observed in this study. 21 It may be due to the small number of patients enrolled, so the sample size needs to be expanded in the follow-up research for continued observation.
It was reported that 60.0% of the phase I studies provided no statistical justification of the expansion cohort sample sizes. The average sample size of a phase I study has increased from 33.8 patients to 73.1 patients from 1988 to 2012. 31 However, it is a limitation that we did not perform a sample size calculation because this trial was designed as a phase I study. There are 49 patients enrolled in this clinical trial. In the future study, we will recommend that phase I studies justify their planned sample sizes so that any predefined expectation of benefit is stated a priori and provide unambiguous rules determining study completion and success.
Conclusions
This study showed that rh-endostatin injection has good safety and tolerability in all dose groups when administered as a single dose or daily for 14 days. A phase II clinical trial at a dose of 10 mg/m2 is recommended to further evaluate the efficacy and safety of this drug in oncology patients.
Authors Contribution
XW and YS wrote the manuscript; XW, YS, and YJ treated patients and/or gathered data. YZC and ZT designed the study; XW, YZC, and WZ evaluated the data; all authors critically read and contributed to the manuscript; all authors read and approved the final manuscript.
Ethics Approval and Consent to Participate
Each included patient signed an informed consent form prior to enrollment. The Tianjin Medical University Cancer Institute and Hospital ethics committee approval number is E2016138. This study was registered retrospectively at the Research Registry https://www.researchregistry.com/ with Registration number 7187.
Footnotes
Declaration of Conflicting Interests
Funding
ORCID iD
